Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 50,396 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose Clear all
Completed Phase 2 Interventional

A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence

NCT00749632
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
oxybutynin
Drug
Lead sponsor
FemmePharma Global Healthcare, Inc.
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

Acellular Adipose Tissue (AAT) for Soft Tissue Reconstruction

NCT03544632
View directory record Official record
Conditions
Soft Tissue Injuries, Trauma
Interventions
Acellular Adipose Tissue (AAT)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 24, 2026, 5:09 PM EDT
Completed No phase listed Observational

Impact of Opioid Avoidance Protocol for ACL Reconstruction

NCT06340932
View directory record Official record
Conditions
ACL Tear, Post Operative Pain
Interventions
Iovera, Celecoxib, Acetaminophen, Oxycodone, Tramadol, Bupivacaine Hydrochloride, Acetaminophen 500Mg Cap
Device · Drug
Lead sponsor
Matthew Varacallo
Other
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
DuBois, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 24, 2026, 5:09 PM EDT
Recruiting Phase 2 Interventional

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

NCT07108998
View directory record Official record
Conditions
CLL/SLL, CLL, SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma Variant, Chronic Lymphocytic Leukemia Variants
Interventions
Epcoritamab
Drug
Lead sponsor
Zulfa Omer
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

NCT04722887
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors

NCT04334863
View directory record Official record
Conditions
Brain Tumor, Medulloblastoma, Brain Metastases
Interventions
WP1066
Drug
Lead sponsor
Emory University
Other
Eligibility
3 Years to 25 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

NCT02218021
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Samidorphan, Placebo, Oxycodone
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 24, 2026, 5:09 PM EDT
Terminated Phase 2 Interventional Results available

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03616821
View directory record Official record
Conditions
Ulcerative Colitis, IBD
Interventions
Brazikumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 24, 2026, 5:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

NCT03033914
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 24, 2026, 5:09 PM EDT
Terminated Phase 1 Interventional

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

NCT02070406
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis
Drug · Biological · Radiation + 2 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

NCT03254784
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165 Capsule, BMS-986165 Tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 24, 2026, 5:09 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Microdosing ICG for Serial Colonic Perfusion Study During Surgery

NCT06254833
View directory record Official record
Conditions
Perfusion; Complications
Interventions
micro dosing of ICG
Other
Lead sponsor
Shanglei Liu
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 24, 2026, 5:09 PM EDT
Recruiting Phase 2 Interventional

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Polatuzumab vedotin, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
73
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Gene Transfer Study for Hemophilia A

NCT03003533
View directory record Official record
Conditions
Hemophilia A
Interventions
SPK-8011
Genetic
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
Sacramento, California • Gainesville, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 24, 2026, 5:09 PM EDT
Withdrawn Phase 1 Interventional

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

NCT05894447
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Naptumomab Estafenatox, Pembrolizumab, Obinutuzumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

NCT02063958
View directory record Official record
Conditions
Cancer
Interventions
SNX-5422
Drug
Lead sponsor
Esanex Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • Stanford, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers

NCT00999128
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GDC-0941, rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 24, 2026, 5:09 PM EDT
Not listed Phase 1Phase 2 Interventional

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

NCT00002628
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
3
States / cities
Indianapolis, Indiana • St Louis, Missouri • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

NCT03339128
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
26
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Corona, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125

NCT02673567
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TEV-48125 - 1, TEV-48125 - 2, TEV-48125 - 3, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Results available

Epidural Neostigmine for Labor Pain

NCT00779467
View directory record Official record
Conditions
Labor Pain
Interventions
Neostigmine, Bupivacaine, fentanyl
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 24, 2026, 5:09 PM EDT
Recruiting Phase 2 Interventional

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

NCT05765500
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Relugolix, Leuprolide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 5:09 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

NCT01080807
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Matching Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 24, 2026, 5:09 PM EDT
Active, not recruiting Not applicable Interventional

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

NCT01652092
View directory record Official record
Conditions
SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Interventions
Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Melphalan, Alemtuzumab 0.2 mg, Fludarabine phosphate 30 mg, MESNA
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 50 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 24, 2026, 5:09 PM EDT